Front Page

UK

World

Business

Sci/Tech

Sport

Despatches

World Summary


On Air

Cantonese

Talking Point

Feedback

Low Graphics

Help

Site Map

Tuesday, February 24, 1998 Published at 02:10 GMT



Business

Drug giants scrap merger
image: [ SmithKline Beecham: behind popular brands ]
SmithKline Beecham: behind popular brands

A merger which would have created the world's largest pharmaceutical company has been called off.

It follows the collapse of talks between SmithKline Beecham and Glaxo Wellcome.


[ image: Unions feared job losses]
Unions feared job losses
If the two had joined forces they would have also have become the second biggest firm of any kind, after General Electric.

But discussions were terminated on Monday evening with Smithkline citing "insurmountable differences."

In its announcement, the company said the negotiations began falling apart on Friday after Glaxo sought to change terms of the tentative deal announced on January 30.

That created the differences that left the two British drug makers unable to agree terms, SmithKline said.

The company added that the discussions since Friday had "revealed a number of differences between the companies, including differences in the approach to the possible merger, management philosophy and corporate culture."


[ image:  ]
SmithKline said its board had unanimously decided against recommending the merger to shareholders.

Glaxo said the firms were unable to "achieve conclusions to the discussions." The company said it would not be looking for an alternative merger partner.

The cancellation of the merger could send share prices of the two companies tumbling on the financial markets, although their employees are likely to be relieved as there would have been thousands of job losses.

Many analysts had considered the merger a fait accompli because all major issues appeared to have been resolved.

The original plan decided senior management positions, gave Glaxo a majority 59.5% share and left the merged company in Britain.

The two companies had viewed merging as a way to boost their research and development budgets.

When the proposed merger was first revealed the stocks of both companies surged in price. SmithKline had a market value of about $70 billion (£43 billion) and Glaxo Wellcome $96 billion (£57 billion) before the talks were announced.
 





Back to top | BBC News Home | BBC Homepage

©

Link to BBC Homepage

  Relevant Stories

24 Feb 98 | Business
Failed merger triggers shares wipeout

24 Feb 98 | Business
Drug giants in their own right

02 Feb 98 | Business
Transatlantic shares frenzy

31 Jan 98 | Business
Drugs merger could threaten jobs, warns union

31 Jan 98 | Business
Drug companies in merger talks

 
  Internet Links

Glaxo Wellcome

SmithKline Beecham


The BBC is not responsible for the content of external internet sites.
 
In this section

Microsoft trial mediator welcomed

Vodafone takeover battle heats up

EU fraud: a billion dollar bill

NatWest bid timetable frozen

No longer Liffe as we know it

France faces EU action over electricity

Inquiry into energy provider loyalty

The growing threat of internet fraud

Christmas turkey strike vote

Brown considers IMF job

Train robbery game hope for SCi

From Sport
League to rule on Sky shares

Mannesmann fights back

Online share dealing triples

Chinese imports boost US trade gap

Pace enters US cable heartland

The rapid rise of Vodafone

Storehouse splits up Mothercare and Bhs

Brown's bulging war-chest

The hidden shopping bills

Europe's top net stock

House passes US budget

Rate fears as sales soar

Safeway faces cash demand probe

Mitchell intervenes to help shipyard

Maxwell pledge to pensioners

Power cuts spark union warning

New factory creates 500 jobs

Drugs company announces 300 jobs

Oil reaches nine-year high

'Asian management culture must change'

US 'prepared for Millennium Bug'

Gucci on a spending spree





Business Contents

Your Money
Market Data
Economy
Companies
Business Basics
E-Commerce